

RAKOVINA THERAPEUTICS INC.
(the “Company”)

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that an annual general meeting (the “**Meeting**”) of the shareholders of Rakovina Therapeutics Inc. (the “**Company**”) will be held at the offices of Blake, Cassels & Graydon LLP, 595 Burrard Street, Suite 2600, Vancouver, British Columbia at 10:00 a.m. (Vancouver time) on June 23, 2022 for the following purposes:

1. to receive the audited financial statements of the Company for its fiscal year ended December 31, 2021 and 2020, the report of the auditor thereon and related management discussion and analysis;
2. to elect the directors of the Company for the ensuing year;
3. to appoint Davidson & Company LLP as auditors of the Company until the next annual meeting of the Company and to authorize the directors of the Company to fix the auditors’ remuneration;
4. to consider and, if thought advisable, to approve by ordinary resolution the Company’s amended and restated omnibus equity incentive plan as more particularly described in the Company’s Management Information Circular (the “**Circular**”) accompanying this Notice of Meeting;
5. to consider and, if thought advisable, to approve, with or without variation, an ordinary resolution of disinterested shareholders of the Company, the full text of which is set forth in the Circular, authorizing the Company to make certain amendments to the Company’s existing escrow agreement to reduce the length of the term of any escrow provision to an 18-month escrow term, as permitted by Section 15.3 of the TSX Venture Exchange’s Policy 2.4 – *Capital Pool Companies*; and
6. to transact such other business as may properly be brought before the Meeting.

Further information regarding the above items is set out in the Circular. Only shareholders of record at the close of business on May 19, 2022 are entitled to notice of and to attend and vote at the Meeting or any adjournment or postponement thereof.

Shareholders who are unable to attend the Meeting in person may vote their shares by completing, signing and returning the accompanying form of proxy to the transfer agent of the Company, Odyssey Trust Company, no less than 48 hours (excluding Saturdays, Sundays and holidays) prior to the Meeting or by completing, signing and delivering the accompanying form of proxy to the Chairman of the Meeting prior to its commencement.

Information with respect to voting by non-registered beneficial shareholders is included in the Circular. Non-registered beneficial shareholders should seek instructions on how to vote their shares from their broker, investment dealer, bank, trust company or other intermediary.

Note of Caution Concerning the COVID-19 Outbreak

At the date of publication of this Notice of Meeting and the accompanying Circular it is the intention of the Company to hold the Meeting at the location stated above in this Notice of Meeting. We are continuously monitoring development of the current coronavirus (COVID-19) outbreak (“**COVID-19**”). **In light of the rapidly evolving public health guidelines related to COVID-19, we ask shareholders to consider voting their shares by proxy and not attend the Meeting in person.** Those shareholders who do wish to attend the Meeting in person, should carefully consider and follow the instructions of the federal Public Health Agency of Canada:

